Top 50 Ai For Genomics

Genomenon develops the Mastermind Genomic Intelligence Platform, which utilizes AI to analyze and interpret extensive genomic datasets, providing actionable insights for clinical diagnostics and precision therapeutics. The platform enhances variant interpretation efficiency, enabling healthcare professionals to make informed decisions based on a comprehensive database of over 26 million curated genomic variants.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

The startup employs AI algorithms to analyze genetic data for identifying mutations associated with hereditary diseases. This technology enables healthcare providers to deliver accurate diagnoses and tailored treatment plans for patients with genetic disorders.

Cypher AI provides an AI‑powered platform that automates the analysis of large genomic and proteomic datasets. By applying deep‑learning models, it predicts variant effects, profiles gene expression, and prioritizes therapeutic targets, delivering annotated results, confidence scores, and visualizations through a secure web interface and API integration for pharma, biotech, and academic researchers.

Emedgene utilizes AI algorithms to analyze genomic data for diagnostics and discovery, enabling healthcare providers to identify genetic conditions more efficiently. The platform enhances the accuracy of genomic interpretations, reducing the time and cost associated with traditional diagnostic methods.

MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.

Reticular offers AI‑driven genetic screening tools that generate interpretable risk assessments for multiple hereditary conditions across an individual’s family history. The platform integrates genomic data with clinical information to provide a comprehensive health picture, enabling clinicians and consumers to make informed preventive or treatment decisions. Revenue is generated through subscription‑based access to the analytics suite and per‑test licensing for healthcare providers.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.

Verge Genomics utilizes a proprietary all-in-human, AI-powered drug discovery platform that integrates machine learning with a large multi-omics database derived from human tissue. The company focuses on developing effective treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis, by rapidly translating insights from human biology into drug candidates.

Curenetics utilizes an AI-powered platform that integrates genomics, imaging, and clinical data to predict individual patient responses to cancer therapies. This technology addresses the high variability in treatment effectiveness, enabling personalized treatment plans that improve patient outcomes and reduce unnecessary healthcare costs.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

This company offers genomic data interpretation services to identify optimal cancer therapies based on individual patient sequencing. Their platform analyzes genomic data to provide personalized insights for cancer treatment and risk assessment. By combining data integration, predictive modeling, and visualization, they enable doctors to tailor surveillance and risk-reduction strategies for patients.

OMGene uses AI to analyze genetic data, providing personalized recommendations for career development, mental well-being, and healthy aging. The platform delivers actionable insights based on individual genetic predispositions.

Onc.ai develops AI models leveraging oncology real-world data, including imaging, EMR, and genomics, to enhance precision oncology. The company's deep learning imaging AI aims to bring clarity to cancer treatment decision-making for medical oncologists. Initial products focus on predicting clinical outcomes in metastatic lung cancer to support pharmaceutical clinical development.

Intelliseq provides a cloud-based platform for automated analysis and clinical interpretation of Next Generation Sequencing (NGS) genetic data, enabling users to generate actionable insights without requiring bioinformatics expertise. The platform addresses the need for efficient and accurate genomic diagnostics by offering customizable workflows for various medical applications, including diagnostics, therapy, and prevention.

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

Quantgene provides a liquid biopsy platform that utilizes precision genomics and advanced medical intelligence to detect cancer signals at earlier stages. This technology enables hospitals to implement efficient cancer screening and genetic testing solutions, improving patient outcomes and operational profitability.

Provides an integrated platform for low-pass whole genome sequencing, combining assay development, scalable sequencing, and cloud-based data analytics to deliver cost-effective genomic insights. Enables applications in human, plant, and animal genomics, such as predicting disease risk, identifying genetic traits, and optimizing breeding strategies, while streamlining data processing and management for researchers and industry professionals.

CassidyBio offers an AI‑driven genomic foundation model that predicts optimal guide RNAs, editors, and delivery contexts for therapeutic gene‑editing projects. By training on proprietary high‑throughput wet‑lab and sequencing data, the platform reduces experimental cycles from months or years to weeks, accelerating the design of clinical‑grade genome‑editing therapies for biotech, pharma, and academic researchers.

Ophiomics develops in vitro diagnostic devices that utilize artificial intelligence and genomics to enhance early cancer detection and optimize treatment selection. Their technology integrates machine learning algorithms with clinical and biomarker data to improve decision-making for clinicians, ultimately aiming to enhance patient outcomes in oncology.

Enigma Genomics utilizes next-generation sequencing technologies and artificial intelligence to decode individual genomes, providing personalized genetic insights that inform health decisions. The platform enables users to access and control their genetic data for life, facilitating proactive disease prevention and tailored medical treatments.

Takenoti offers an intelligence layer for gene editing through a genomic foundation model that predicts optimal guide RNAs, editor proteins, and delivery vectors for therapeutic applications. By leveraging large-scale wet‑lab datasets and high‑throughput NGS validation, the platform reduces experimental trial‑and‑error cycles from years to weeks, enabling biotech and pharma teams to design safe, effective gene‑editing therapies faster and at scale.

Canomiks utilizes a genomics and AI-based platform to validate and certify the biological efficacy and safety of ingredients in dietary supplements, functional foods, beverages, and cosmeceuticals. The company addresses the need for transparency and trust in the formulation of health products, ensuring they are both safe and effective for consumers.

The startup utilizes polymathic AI to deliver precision medicine by analyzing complex biological data and patient information. This approach enhances treatment personalization, improving patient outcomes in healthcare by tailoring therapies to individual genetic profiles.

The startup develops AI-powered precision medicine technology that utilizes multi-omics analysis to decode cellular health and identify molecular causes of diseases. This approach enhances early disease detection and enables targeted therapies for non-invasive prenatal and oncology testing.

DNAstack offers Omics AI, a software suite that enables the secure connection, protection, and analysis of federated omics and health data using AI-powered tools compliant with Global Alliance for Genomics & Health standards. This platform addresses the challenge of accessing and analyzing large, sensitive datasets without the need to move them, facilitating collaborative research across distributed networks.

This startup offers a clinical genome interpretation platform that uses AI algorithms to analyze genomic data from various sources. The platform delivers actionable genomic insights to medical professionals, enabling faster and more accurate diagnostic reports.

My Genome Screen provides an AI-powered platform that accelerates rare disease diagnosis by efficiently interpreting genetic variants. Its system prioritizes disease-causing mutations from complex genomic data, enabling clinicians to identify genetic disorders faster and facilitate targeted treatments.

General Genomics develops AI/ML-powered bioinformatics solutions for government and commercial clients. The company provides data-driven tools, including synthetic data generation via SYN46™, to enhance analytics and streamline complex data workflows. Their services focus on delivering tailored informatics and data governance for sectors like public health, pharmaceuticals, and national security.

Deargen utilizes deep learning algorithms for genome data analysis, biomarker prediction, and drug-target interaction modeling to facilitate the discovery and optimization of new therapeutic molecules. The platform addresses the challenge of developing effective treatments for complex diseases by enabling precision medicine through targeted drug design.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

This company utilizes a machine learning platform integrating genomics, transcriptomics, and proteomics to identify novel, druggable protein targets across the entire human genome. Their methodology discovers noncanonical proteins previously overlooked by conventional drug discovery, offering new therapeutic avenues for over 1300 human diseases. The resulting target portfolio provides a substantial, validated resource for developing treatments against complex and difficult-to-treat conditions.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

The startup operates a biomarker discovery platform that utilizes artificial intelligence and genomic analysis techniques to identify personalized cancer therapies for patients. This approach enhances patient stratification, enabling healthcare providers to deliver more effective treatment options tailored to individual needs.

The startup develops a genomics platform that enhances genetic testing accuracy by analyzing the functional significance of genetic variations and mutations in the human genome. This technology enables improved interpretation of genetic tests for rare diseases and cancer, facilitating the conversion of generic drugs into targeted precision medicines.

The startup operates a genomics analytics platform that provides clinical genome reporting and AI-driven insights for monogenic and polygenic risk assessment, pharmacogenomics, and wellness traits. This technology enables healthcare providers to make informed decisions based on precise genomic data, enhancing patient care and research capabilities.

enGenome offers the eVai platform, which utilizes AI and guideline-based classification to accurately interpret genomic variants for early diagnosis of rare diseases. This technology enhances clinical decision-making by providing precise genetic diagnoses, addressing the challenge of variant interpretation in translational research and routine healthcare.

SIVOTEC BioInformatics offers the GENA AI platform, which automates the analysis of SNP Array genetic test data for rare disease identification. This platform helps commercial labs, hospitals, and academic centers accelerate diagnosis by significantly reducing the manual effort and time required to correlate genetic data with over 7,000 rare diseases.

The startup utilizes artificial intelligence and genetic analysis to enhance healthcare innovation by identifying and developing targeted therapies. This approach addresses the inefficiencies in drug discovery and personalized medicine, aiming to accelerate the delivery of effective treatments to patients.

Unite Genomics provides an AI-powered health insights platform that integrates and analyzes electronic health records (EHRs) from over 2,600 health systems, covering more than 80% of the U.S. population. The platform enables rapid access to patient data, facilitating personalized treatment eligibility assessments and streamlining clinical trial enrollment processes.

Aegicare is an AI-driven platform that provides clinical whole-genome sequencing solutions, utilizing proprietary bioinformatics tools to deliver precise genetic analysis and rare disease interpretation. The platform addresses the challenge of accurate diagnosis in complex genetic conditions, enhancing patient care through tailored genomic insights.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

OutSee develops computational algorithms for genomic analysis to identify therapeutic targets for precision medicine. The company enhances drug discovery by providing accurate insights into genetic variations that influence treatment efficacy.

Omabit provides an AI‑driven platform that lets biologists and researchers upload sequencing files and ask plain‑English questions to receive structured, reproducible genomic analysis results without writing pipelines. The service automatically handles tasks such as pathway enrichment against KEGG, Reactome and GO, and fuzzy‑matches sample IDs across datasets, delivering traceable, exportable outputs for drug trial studies.

The startup develops an artificial intelligence-based medical device for self-measurement of sleep apnea, integrating sensor technology and genomics to enhance diagnostic accuracy and treatment monitoring. This platform addresses the growing demand for efficient disease prevention and management in healthcare, particularly in response to an aging population.

The startup develops a bioinformatics platform that utilizes DNA sequence manipulation techniques, including alignment, variant calling, and functional annotation, to identify genes associated with specific functions. This enables biotechnology and pharmaceutical companies to conduct mutational analysis for verifying genetic modifications, thereby enhancing product design and accelerating research timelines.

GV20 Therapeutics utilizes its STEAD platform, which integrates AI, genomics, and cancer biology, to develop antibody therapeutics targeting specific cancer pathways. This approach aims to create effective cancer treatments more rapidly and at a lower cost than traditional drug development methods.

Biostate AI integrates biological samples, multi-omics data, and AI to advance precision health solutions globally. The company develops proprietary sequencing technologies, such as BIRT and PERD, to generate cleaner, cost-effective genomic data for earlier disease detection. Through subsidiaries, Biostate AI focuses on population-scale health management, autonomous scientific research, and intelligent diagnostics implementation.

The startup operates a genomics data management and analytics platform that centralizes disparate genomic datasets in secure on-premise or cloud environments. This platform enhances research and development efficiency by ensuring data integrity, reducing operational costs, and accelerating the time to market for genomic insights.